This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y
by Zacks Equity Research
Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.
Pacific Biosciences (PACB) Loss In Line With Estimates in Q2
by Zacks Equity Research
Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.
The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.
Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.
Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.
AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.
Tariff Woes Haunt Wall Street: Take Refuge in These 5 Stocks
by Tirthankar Chakraborty
Companies involved in artificial intelligence, e-commerce, biotechnology and gaming businesses are immune to trade conflicts. They are part of an evolving trend that provides stability during tough times and their quest for the next big thing fuels growth.
Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Illumina (ILMN)
by Madeleine Johnson
Invest in the medical space with this DNA sequencing-focused company.
Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates
by Zacks Equity Research
Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.
Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Solid performance in the Global Industrial and Global Institutional segments boost Ecolab's (ECL) top line in Q2.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.
athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View
by Zacks Equity Research
An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.
Sprint (S) Gears Up for Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Sprint (S) is likely to report lower revenues in first-quarter fiscal 2018 on a year-over-year basis due to weak demand patterns in the industry.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
Abiomed (ABMD) Lags Q1 Earnings Estimates, Raises '19 View
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella line continues to drive growth in Q1. A strong guidance instills investors' optimism.
Why Earnings Season Could Be Great for Illumina (ILMN)
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG